Dr. David Billmeier, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
Medicare and federal program status
Opted out of Medicare from July 1, 2024 through July 1, 2028. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated August 14, 2026). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 50
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
FL license ME71479
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 50
- Services billed
- 75
- Patients’ average age
- 80
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 137 | 91 |
| Established patient office or other outpatient visit, 20-29 minutes | 101 | 61 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 45 | 45 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 6 payments worth $815 in total to this clinician.
| Pacira Pharmaceuticals Incorporated | $764 |
|---|---|
| Celgene Corporation | $26.94 |
| Pfizer Inc. | $23.47 |
| Travel and Lodging | $439 |
|---|---|
| Food and Beverage | $376 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pacira Pharmaceuticals Incorporated May 17, 2025 | Travel and Lodging travel to Tampa, FL · in-kind | $219 |
| Pacira Pharmaceuticals Incorporated May 16, 2025 | Travel and Lodging travel to Tampa, FL · in-kind | $219 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 9 companies. The companies reported $1,060,422 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Eli Lilly and Company · Active, not recruiting · NCT06260722 - Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Alnylam Pharmaceuticals Inc. - A phase one,randomized,double blind,placeb controlled,multi centre study to assess the pharmacodynamics,safety,and tolerability of azd4144 in participants with established atherosclerotic cardiovascular and chronic ki…
AstraZeneca UK Limited - A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agit…
Celgene Corporation - A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agit…
E.r. Squibb & Sons, L.l.c. - LX9211.1-204-DPN
Lexicon Pharmaceuticals, Inc. - A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment …
Novartis Pharmaceuticals Corporation - A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT05511363 - A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06585787
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.